Bayer's Fortnight of Truth: A Legal Showdown and a Clinical Breakthrough

Bayer faces a pivotal US Supreme Court hearing on glyphosate litigation while its stroke drug Asundexian shows strong Phase III results, offering a potential blockbuster.

Investors in Bayer are bracing for a pivotal two-week period that will test both the company's legal defenses and its pharmaceutical pipeline's promise. The dual catalysts—a critical US Supreme Court hearing and a major clinical breakthrough—arrive as the stock shows tentative signs of recovery from a prolonged slump.

The most immediate pressure point is legal. On April 27, Bayer will appear before the US Supreme Court for a hearing on the glyphosate litigation complex. This session is viewed as potentially decisive for the multi-billion dollar legal overhang that has weighed on the company's valuation for years. The outcome will likely shape the investment narrative for Bayer well into the future.

Simultaneously, the company's research division has delivered a significant win. Full Phase III data for the anticoagulant Asundexian, published in the New England Journal of Medicine, show a clear benefit in stroke prevention. The OCEANIC-STROKE study, involving over 12,000 participants, demonstrated that the drug reduced recurrent ischemic strokes by 26 percent compared to a placebo. Crucially, the incidence of major bleeding events was not increased—a critical advantage where previous blood thinners have failed. The drug works by selectively inhibiting Factor XIa, a protein key to clot formation but less involved in natural wound healing.

This clinical success marks a dramatic turnaround for Asundexian, which faced a major setback in a different indication late last year. The US FDA has already granted it Fast-Track status, and Bayer has initiated global regulatory discussions. With approximately 12 million people suffering a stroke worldwide each year, analysts see blockbuster potential, with peak annual sales estimates reaching one billion euros. The drug is a central pillar of Bayer's long-term growth strategy through 2030.

Financially, the company is navigating a mixed landscape. Management, led by CEO Bill Anderson, has outlined clear operational targets for 2026: adjusted EBITDA is projected between 9.6 and 10.1 billion euros, with Core EPS expected in a range of 4.30 to 4.80 euros. However, the free cash flow outlook is less encouraging, forecasted at negative 1.5 to 2.5 billion euros for the year, which includes roughly 5 billion euros provisioned for ongoing litigation. Reducing net debt, projected to be 32-33 billion euros by year-end, remains a persistent challenge. The subdued financial posture is reflected in a dividend of 0.11 euros per share, payable on April 29.

Operational bright spots are emerging within the pharmaceutical division. The drug Kerendia, which recently gained a new EU approval for heart failure, saw currency-adjusted sales surge by 88 percent. Management has set a long-term sales target exceeding three billion euros for this product. In the near term, the company is banking on Nubeqa and Kerendia as key revenue drivers.

The stock market has begun to acknowledge these developments. Bayer shares have gained nine percent over the past month, closing Friday at 41.10 euros, a level that suggests a break from its longer-term downtrend. The stock currently trades around its 50-day moving average, a technically neutral position, though it remains roughly 16 percent below its 52-week high from February. Recent upgrades, including a lowered risk warning from Sustainalytics regarding glyphosate liabilities, have also provided support.

The upcoming quarterly report on May 12 will offer the next tangible data point, potentially confirming cost-saving measures. For the full year, Bayer anticipates an operating profit of approximately ten billion euros. Yet, with the Supreme Court hearing just days away, that earnings release may struggle to capture the market's full attention. The verdict from Washington will ultimately determine whether Bayer's recent momentum can be sustained or if old legal shadows will once again dominate its story.